Novartis Investigative Site

Ste-Foy, Quebec G1W 4R4

0 studies enrolling now · 7 studies all time

What they study most

Atherosclerosis, Cardiovascular Disease, Familial Chylomicronemia Syndrome (FCS), Familial Chylomicronemia Syndrome (FCS) (HLP Type I), Hypertension, Non Familial Chylocmicronemia Syndrome (Non-FCS), Systolic Hypertension, Type 2 Diabetes Mellitus

Studies at this site

• A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. — Stopped early
• An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension — Completed
• Efficacy and Safety of LCZ696A in Patients With Essential Hypertension — Completed
• A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early